Abstracts tagged "Lupus nephritis"

Abstract Number: 0107 • ACR Convergence 2022
Short-, Intermediate- and Long-Term Renal Outcomes in Hispanics from Puerto Rico with Lupus Nephritis: Induction Therapy with Cyclophosphamide vs. Mycophenolate Mofetil
Suheiry Márquez, Dahima Cintrón and Luis Vilá, University of Puerto Rico Medical Sciences Campus, San Juan, PR
Background/Purpose: The American College of Rheumatology (ACR) guidelines for the treatment of class III and class IV lupus nephritis (LN) recommend induction therapy with mycophenolate…
Abstract Number: 0537 • ACR Convergence 2022
Neutrophil Extracellular Traps as a Biomarker to Predict Outcomes in Lupus Nephritis
Laura Patricia Whittall Garcia¹, Farnoosh Naderinavi¹, Zahi Touma², Dafna Gladman³, Murray Urowitz⁴, Anna Konvalinka¹ and Joan Wither⁵, ¹University Health Network, Toronto, ON, Canada, ²Schroeder Arthritis Institute, Krembil Research Institute, University Health Network and University of Toronto, Toronto, ON, Canada, ³Toronto Western Hospital, Schroeder Arthritis Institute, Toronto, ON, Canada, ⁴University of Toronto, University Health Network, Schroeder Arthritis Institute, Toronto, ON, Canada, ⁵Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, University of Toronto, Toronto, ON, Canada
Background/Purpose: Neutrophil Extracellular Traps (NETs) have been implicated in Lupus Nephritis (LN) pathogenesis. SLE neutrophils release High Mobility Group Box-1 (HMGB1) protein, in turn, HMGB1…
Abstract Number: 0949 • ACR Convergence 2022
Systemic Lupus Erythematosus Women with Lupus Nephritis in Pregnancy Therapeutic CHallenge (SWITCH): The Systemic Lupus International Collaborating Clinics Experience
Joo Young (Esther) Lee¹, Arielle Mendel², Anca Askanase³, Sang-Cheol Bae⁴, Jill Buyon⁵, Ann E Clarke⁶, Nathalie Costedoat-Chalumeau⁷, Paul R Fortin⁸, Dafna Gladman⁹, John Hanly¹⁰, Murat Inanc¹¹, David Isenberg¹², Anselm Mak¹³, Marta Mosca¹⁴, Michelle Petri¹⁵, Anisur Rahman¹⁶, Rosalind Ramsey-Goldman¹⁷, Jorge Sanchez-Guerrero¹⁸, Murray Urowitz¹⁹, Daniel Wallace²⁰, Sasha Bernatsky²¹ and Evelyne Vinet², ¹McGill University, Montréal, QC, Canada, ²McGill University Health Centre, Montréal, QC, Canada, ³Columbia University Medical Center, New York, NY, ⁴Hanyang University Medical Center, Seoul, Republic of Korea, ⁵NYU Grossman School of Medicine, New York, NY, ⁶University of Calgary, Division of Rheumatology, Cumming School of Medicine, Calgary, AB, Canada, ⁷Inserm DR Paris 5, Paris, France, ⁸Centre ARThrite - CHU de Québec - Université Laval, Québec, QC, Canada, ⁹Toronto Western Hospital, Schroeder Arthritis Institute, Toronto, ON, Canada, ¹⁰Division of Rheumatology, Queen Elizabeth II Health Sciences Center (Nova Scotia Rehabilitation Site) and Dalhousie University, Halifax, NS, Canada, ¹¹Division of Rheumatology, Department of Internal Medicine, Istanbul Medical Faculty, Istanbul University, Istambul, Turkey, ¹²University College London, London, United Kingdom, ¹³Division of Rheumatology, Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore, ¹⁴Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy, ¹⁵Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, MD, ¹⁶Centre for Rheumatology, Department of Medicine, University College London, London, United Kingdom, ¹⁷Northwestern University Feinberg School of Medicine, Chicago, USA, Chicago, IL, ¹⁸Sinai Health System, Toronto, ON, Canada, ¹⁹University of Toronto, University Health Network, Schroeder Arthritis Institute, Toronto, ON, Canada, ²⁰Cedars-Sinai Medical Center, Los Angeles, CA, ²¹Research Institute of the McGill University Health Centre, Montréal, QC, Canada
Background/Purpose: One-third of women with SLE develop lupus nephritis (LN), and most receive mycophenolate mofetil (MMF). However, MMF is teratogenic, and needs to be switched…
Abstract Number: 1462 • ACR Convergence 2022
Exploring the Potential of Urine: Serum Fractional Excretion Ratios as Disease Biomarkers in Active Lupus Nephritis
Samar Soliman¹, Samantha Stanley², Kamala Vanarsa², Faten Ismail³, Chi Chiu Mok⁴ and Chandra mohan⁵, ¹Rheumatology Department, Faculty of Medicine, Minia university, Minya, Egypt, ²Department of Biomedical Engineering, University of Houston, Houston, TX, ³Department of Rheumatology, Faculty of Medicine, Minia University, Minia, Egypt, ⁴Tuen Mun Hospital, Hong Kong, China, ⁵University of Houston, Houston, TX
Background/Purpose: The goal of this exploratory study is to determine if urine:serum fractional excretion ratios can outperform the corresponding urinary biomarker proteins in identifying active…
Abstract Number: 1932 • ACR Convergence 2022
Efficacy of the COVID-19 Vaccine in Pediatric Systemic Lupus Erythematosus Patients
Yi Shi¹, Catherine Park², Sangeeta Sule² and Sun-Young Ahn², ¹Children's National Hospital, New York, NY, ²Children's National Hospital, Washington, DC
Background/Purpose: The COVID-19 virus has caused significant morbidity and mortality, despite introduction of the COVID vaccine. Immunocompromised patients have been shown to have reduced response…
Abstract Number: 0221 • ACR Convergence 2022
Identifying and Addressing Gaps in Systemic Lupus Erythematosus Care via Multimodal Continuing Medical Education
Katie Robinson¹, Jillian Scavone¹, William Cioffi¹, Robert Esgro¹ and Leonard Calabrese², ¹Vindico Medical Education, Thorofare, NJ, ²Cleveland Clinic, Cleveland, OH
Background/Purpose: Given the recent advances in the management of patients systemic lupus erythematosus (SLE), rheumatology and primary care providers are challenged to administer the latest…
Abstract Number: 0538 • ACR Convergence 2022
Contemporary Incidence of Lupus Nephritis Among Patients with Systemic Lupus Erythematosus in the United States
April Jorge¹, Baijun Zhou¹, Jacquelyn Nestor¹, yuqing zhang² and Hyon Choi³, ¹Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hospital, Quincy, MA, ³MASSACHUSETTS GENERAL HOSPITAL, Lexington, MA
Background/Purpose: Lupus nephritis is a leading cause of morbidity in patients with systemic lupus erythematosus (SLE). We sought to determine the incidence of lupus nephritis…
Abstract Number: 0976 • ACR Convergence 2022
Low-dose Belimumab and Antimalarial Agents Prevent Renal Flares in Systemic Lupus Erythematosus: Results from Four Randomised Clinical Trials
Alvaro Gomez¹, Sandra Jägerback¹, Christopher Sjöwall² and Ioannis Parodis³, ¹Division of Rheumatology, Department of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden, ²Department of Biomedical and Clinical Sciences, Division of Inflammation and Infection, Linköping University, Linköping, Sweden, ³Karolinska Institutet, Stockholm, Sweden
Background/Purpose: Renal flares contribute substantially to morbidity, renal survival and death in systemic lupus erythematosus (SLE). Identification of pharmacological strategies for the prevention of renal…
Abstract Number: 1463 • ACR Convergence 2022
Short- and Long-Term Progression of Kidney Involvement in Systemic Lupus Erythematosus Patients with Low-Grade Proteinuria
Shudan Wang¹, Allan Spielman², Mindy Ginsberg², Michelle Petri³, Brad Rovin⁴, Jill Buyon⁵ and Anna Broder⁶, ¹Montefiore Medical Center / Albert Einstein College of Medicine, New York, NY, ²Albert Einstein College of Medicine, Bronx, NY, ³Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, MD, ⁴The Ohio State University, Columbus, OH, ⁵NYU Grossman School of Medicine, New York, NY, ⁶Hackensack University Medical Center, Hackensack, NJ
Background/Purpose: Lupus nephritis remains a common cause of morbidity and mortality in systemic lupus erythematosus (SLE). Current guidelines recommend performing a kidney biopsy at urine…
Abstract Number: 2061 • ACR Convergence 2022
Impact of Time to Remission, Flares and Exposure to Immunosuppressives on the Development of Advanced Chronic Kidney Disease (Stage IV or Worse) in Lupus Nephritis
Dafna Gladman¹, KONSTANTINOS TSELIOS², Jiandong Su³ and Murray Urowitz⁴, ¹Toronto Western Hospital, Schroeder Arthritis Institute, Toronto, ON, Canada, ²McMaster University, Population Health Research Institute, Hamilton, ON, Canada, ³Schroeder Arthritis Institute, Krembil Research Institute, University Health Network and University of Toronto, Toronto, ON, Canada, ⁴University of Toronto, University Health Network, Schroeder Arthritis Institute, Toronto, ON, Canada
Background/Purpose: Lupus nephritis (LN) affects up to 40% of patients with SLE and leads to end stage kidney disease (ESKD) in 17-33% after 10 years.…
Abstract Number: 0319 • ACR Convergence 2022
Factors Associated with Worsening Interstitial Fibrosis/Tubular Atrophy in Lupus Nephritis Patients Undergoing Repeat Kidney Biopsy
Daming Shao¹, Alejandra Londoño Jimenez², Maria Auxiliadora Salgado Guerrero³, Anna Broder⁴ and Shudan Wang⁵, ¹Albert Einstein College of Medicine/Jacobi Medical Center, Bronx, NY, ²McFarland Clinic, Ames, IA, ³University of Alabama at Birmingham, Birmingham, AL, ⁴Hackensack University Medical Center, Hackensack, NJ, ⁵Montefiore Medical Center / Albert Einstein College of Medicine, New York, NY
Background/Purpose: Lupus nephritis (LN) is one of the most severe manifestations of systemic lupus erythematosus (SLE). Approximately 10 to 30% of patients with LN progress…
Abstract Number: 0539 • ACR Convergence 2022
Cardiac Complications, Thrombosis, Infections and All-cause Mortality Among Patients with End-Stage Kidney Disease Due to Lupus Nephritis in the USRDS 2006-2013 According to SLE Medication Use
Anna Broder¹, Wenzhu B. Mowrey², Kazuki Yoshida³ and Karen Costenbader³, ¹Hackensack University Medical Center, Hackensack, NJ, ²Albert Einstein College of Medicine, Bronx, NY, ³Brigham and Women's Hospital, Boston, MA
Background/Purpose: Medication management strategies in patients with lupus-related end stage kidney disease (ESKD) have not been studied. Our prior work has shown that HCQ may…
Abstract Number: 0986 • ACR Convergence 2022
Impact of Weight and Race on Renal Response to Cyclophosphamide in the Abatacept and Cyclophosphamide Combination Efficacy and Safety Study (ACCESS)
Julia Ford, William McCune, Neil Kamdar and Michael O'Leary, University of Michigan, Ann Arbor, MI
Background/Purpose: ACCESS assessed the efficacy of abatacept (ABA) as induction therapy in lupus nephritis (LN), randomizing 134 patients to ABA vs. placebo on a background…
Abstract Number: 1467 • ACR Convergence 2022
Dickkopf Homolog 3 (DKK3) as a Prognostic Marker in Lupus Nephritis: A Prospective Monocentric Experience
Savino Sciascia¹, Alice Barinotti², Massimo Radin², Irene Cecchi¹, Elisa Menegatti², Vittorio Modena², Daniela Rossi², Simone Baldovino², Roberta Fenoglio² and Dario Roccatello², ¹University of Turin, Torino, Italy, ²University of Turin, Turin, Italy
Background/Purpose: Lupus Nephritis (LN) is a major cause of mortality/morbidity in patients affected by Systemic Lupus Erythematosus (SLE). Reliable prognostic markers, especially related to the…
Abstract Number: 2065 • ACR Convergence 2022
Sustained B Cell Depletion in Lupus Nephritis Patients After Treatment with a B Cell Agent Is Associated with Fewer Disease Flares
Diane Zisa¹, Jeffrey Zhang-Sun¹, Paul Christos² and Kyriakos Kirou¹, ¹Hospital for Special Surgery, New York, NY, ²Weill Cornell Medicine/New York-Presbyterian, New York, NY
Background/Purpose: B cell targeting agents (BCA), including belimumab (BEL) and rituximab (RTX), have been used with success in lupus nephritis (LN) patients, though identifying patients…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].